CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma
AimCD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the po...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pathology 2018-09, Vol.71 (9), p.795-801 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 801 |
|---|---|
| container_issue | 9 |
| container_start_page | 795 |
| container_title | Journal of clinical pathology |
| container_volume | 71 |
| creator | Gong, Qi-Xing Wang, Zhen Liu, Chong Li, Xiao Lu, Ting-Xun Liang, Jin-Hua Xu, Wei Li, Jian-Yong Zhang, Zhi-Hong |
| description | AimCD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences.MethodsA total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.ResultsUsing a >0% threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or ‘starry sky’ pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients’ outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.ConclusionCD30+ DLBCL may be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited. |
| doi_str_mv | 10.1136/jclinpath-2018-205039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2027067697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2027067697</sourcerecordid><originalsourceid>FETCH-LOGICAL-b378t-90aea5105c98a54e61f170c790988f390aa9ce5094ecaa0baa9f2b77d9067ec23</originalsourceid><addsrcrecordid>eNqNkcFO3DAQhq2qCLbAIxRZ4tJLytiJ7fgIKQWkRVzaA5dGjjPpZpXEwU4KvD3e7nYPnHqZ0cx882s0PyGfGXxlLJUXa9u1w2imVcKB5TEISPUHsmCZ4knGMvmRLAA4S7TK5BH5FMIagKWKpYfkiGspJRNqQX4V31Kg-DJ6DKF1AzVDTdspUOu8x85Mm95zO63o_WPxd3hVLDltB1ojHdwfR-u2aeaAtDP-N9KrxGLX0e61H1euNyfkoDFdwNNdPiY_v1__KG6T5cPNXXG5TKpU5VOiwaARDITVuREZStYwBVZp0HnepHFstEUBOkNrDFSxbHilVK1BKrQ8PSZftrqjd08zhqns27C5xAzo5lBy4CqiUquInr9D1272Q7wuUho4gMhFpMSWst6F4LEpR9_2xr-WDMqNAeXegHJjQLk1IO6d7dTnqsd6v_Xv4xGALVD16__UfAP0EpFQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2090200585</pqid></control><display><type>article</type><title>CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma</title><source>MEDLINE</source><source>PubMed Central</source><creator>Gong, Qi-Xing ; Wang, Zhen ; Liu, Chong ; Li, Xiao ; Lu, Ting-Xun ; Liang, Jin-Hua ; Xu, Wei ; Li, Jian-Yong ; Zhang, Zhi-Hong</creator><creatorcontrib>Gong, Qi-Xing ; Wang, Zhen ; Liu, Chong ; Li, Xiao ; Lu, Ting-Xun ; Liang, Jin-Hua ; Xu, Wei ; Li, Jian-Yong ; Zhang, Zhi-Hong</creatorcontrib><description>AimCD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences.MethodsA total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.ResultsUsing a >0% threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or ‘starry sky’ pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients’ outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.ConclusionCD30+ DLBCL may be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.</description><identifier>ISSN: 0021-9746</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jclinpath-2018-205039</identifier><identifier>PMID: 29666157</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - genetics ; Chi-Square Distribution ; China ; Female ; Gangrene ; Gene amplification ; Gene expression ; Gene Rearrangement ; Genetic Predisposition to Disease ; Humans ; Immunoglobulins ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Kaplan-Meier Estimate ; Ki-1 Antigen - analysis ; Kinases ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - chemistry ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Medical prognosis ; Middle Aged ; Multivariate Analysis ; Pathology ; Patients ; Phenotype ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Proto-Oncogene Proteins c-bcl-2 - analysis ; Proto-Oncogene Proteins c-bcl-2 - genetics ; Proto-Oncogene Proteins c-myc - analysis ; Proto-Oncogene Proteins c-myc - genetics ; Retrospective Studies ; Risk Factors ; Studies ; Young Adult</subject><ispartof>Journal of clinical pathology, 2018-09, Vol.71 (9), p.795-801</ispartof><rights>Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</rights><rights>2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b378t-90aea5105c98a54e61f170c790988f390aa9ce5094ecaa0baa9f2b77d9067ec23</citedby><cites>FETCH-LOGICAL-b378t-90aea5105c98a54e61f170c790988f390aa9ce5094ecaa0baa9f2b77d9067ec23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29666157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gong, Qi-Xing</creatorcontrib><creatorcontrib>Wang, Zhen</creatorcontrib><creatorcontrib>Liu, Chong</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Lu, Ting-Xun</creatorcontrib><creatorcontrib>Liang, Jin-Hua</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Li, Jian-Yong</creatorcontrib><creatorcontrib>Zhang, Zhi-Hong</creatorcontrib><title>CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><description>AimCD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences.MethodsA total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.ResultsUsing a >0% threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or ‘starry sky’ pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients’ outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.ConclusionCD30+ DLBCL may be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Chi-Square Distribution</subject><subject>China</subject><subject>Female</subject><subject>Gangrene</subject><subject>Gene amplification</subject><subject>Gene expression</subject><subject>Gene Rearrangement</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Kaplan-Meier Estimate</subject><subject>Ki-1 Antigen - analysis</subject><subject>Kinases</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - chemistry</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pathology</subject><subject>Patients</subject><subject>Phenotype</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Proto-Oncogene Proteins c-bcl-2 - analysis</subject><subject>Proto-Oncogene Proteins c-bcl-2 - genetics</subject><subject>Proto-Oncogene Proteins c-myc - analysis</subject><subject>Proto-Oncogene Proteins c-myc - genetics</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Studies</subject><subject>Young Adult</subject><issn>0021-9746</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkcFO3DAQhq2qCLbAIxRZ4tJLytiJ7fgIKQWkRVzaA5dGjjPpZpXEwU4KvD3e7nYPnHqZ0cx882s0PyGfGXxlLJUXa9u1w2imVcKB5TEISPUHsmCZ4knGMvmRLAA4S7TK5BH5FMIagKWKpYfkiGspJRNqQX4V31Kg-DJ6DKF1AzVDTdspUOu8x85Mm95zO63o_WPxd3hVLDltB1ojHdwfR-u2aeaAtDP-N9KrxGLX0e61H1euNyfkoDFdwNNdPiY_v1__KG6T5cPNXXG5TKpU5VOiwaARDITVuREZStYwBVZp0HnepHFstEUBOkNrDFSxbHilVK1BKrQ8PSZftrqjd08zhqns27C5xAzo5lBy4CqiUquInr9D1272Q7wuUho4gMhFpMSWst6F4LEpR9_2xr-WDMqNAeXegHJjQLk1IO6d7dTnqsd6v_Xv4xGALVD16__UfAP0EpFQ</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Gong, Qi-Xing</creator><creator>Wang, Zhen</creator><creator>Liu, Chong</creator><creator>Li, Xiao</creator><creator>Lu, Ting-Xun</creator><creator>Liang, Jin-Hua</creator><creator>Xu, Wei</creator><creator>Li, Jian-Yong</creator><creator>Zhang, Zhi-Hong</creator><general>BMJ Publishing Group LTD</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma</title><author>Gong, Qi-Xing ; Wang, Zhen ; Liu, Chong ; Li, Xiao ; Lu, Ting-Xun ; Liang, Jin-Hua ; Xu, Wei ; Li, Jian-Yong ; Zhang, Zhi-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b378t-90aea5105c98a54e61f170c790988f390aa9ce5094ecaa0baa9f2b77d9067ec23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Chi-Square Distribution</topic><topic>China</topic><topic>Female</topic><topic>Gangrene</topic><topic>Gene amplification</topic><topic>Gene expression</topic><topic>Gene Rearrangement</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Kaplan-Meier Estimate</topic><topic>Ki-1 Antigen - analysis</topic><topic>Kinases</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - chemistry</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pathology</topic><topic>Patients</topic><topic>Phenotype</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Proto-Oncogene Proteins c-bcl-2 - analysis</topic><topic>Proto-Oncogene Proteins c-bcl-2 - genetics</topic><topic>Proto-Oncogene Proteins c-myc - analysis</topic><topic>Proto-Oncogene Proteins c-myc - genetics</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gong, Qi-Xing</creatorcontrib><creatorcontrib>Wang, Zhen</creatorcontrib><creatorcontrib>Liu, Chong</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Lu, Ting-Xun</creatorcontrib><creatorcontrib>Liang, Jin-Hua</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Li, Jian-Yong</creatorcontrib><creatorcontrib>Zhang, Zhi-Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gong, Qi-Xing</au><au>Wang, Zhen</au><au>Liu, Chong</au><au>Li, Xiao</au><au>Lu, Ting-Xun</au><au>Liang, Jin-Hua</au><au>Xu, Wei</au><au>Li, Jian-Yong</au><au>Zhang, Zhi-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma</atitle><jtitle>Journal of clinical pathology</jtitle><addtitle>J Clin Pathol</addtitle><date>2018-09</date><risdate>2018</risdate><volume>71</volume><issue>9</issue><spage>795</spage><epage>801</epage><pages>795-801</pages><issn>0021-9746</issn><eissn>1472-4146</eissn><abstract>AimCD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences.MethodsA total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.ResultsUsing a >0% threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or ‘starry sky’ pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients’ outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.ConclusionCD30+ DLBCL may be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>29666157</pmid><doi>10.1136/jclinpath-2018-205039</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9746 |
| ispartof | Journal of clinical pathology, 2018-09, Vol.71 (9), p.795-801 |
| issn | 0021-9746 1472-4146 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2027067697 |
| source | MEDLINE; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Chi-Square Distribution China Female Gangrene Gene amplification Gene expression Gene Rearrangement Genetic Predisposition to Disease Humans Immunoglobulins Immunohistochemistry In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Ki-1 Antigen - analysis Kinases Lymphoma Lymphoma, Large B-Cell, Diffuse - chemistry Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - pathology Male Medical prognosis Middle Aged Multivariate Analysis Pathology Patients Phenotype Predictive Value of Tests Prognosis Proportional Hazards Models Proto-Oncogene Proteins c-bcl-2 - analysis Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-myc - analysis Proto-Oncogene Proteins c-myc - genetics Retrospective Studies Risk Factors Studies Young Adult |
| title | CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A58%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD30%20expression%20and%20its%20correlation%20with%20MYC%20and%20BCL2%20in%20de%20novo%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Gong,%20Qi-Xing&rft.date=2018-09&rft.volume=71&rft.issue=9&rft.spage=795&rft.epage=801&rft.pages=795-801&rft.issn=0021-9746&rft.eissn=1472-4146&rft_id=info:doi/10.1136/jclinpath-2018-205039&rft_dat=%3Cproquest_cross%3E2027067697%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2090200585&rft_id=info:pmid/29666157&rfr_iscdi=true |